Mammography Devices Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product Type (Full-field Digital Mammography, Film-screen Mammogram, Breast Tomosynthesis), By Technology (Digital, Analog), By End User (Hospitals & Clinics, Diagnostic Centres, Others), By Region & Competition, 2020-2030F

Market Overview

Global Mammography Devices market was valued at USD 2.74 Billion in 2024 and is expected to reach USD 3.84 Billion by 2030 with a CAGR of 5.75%. Mammography devices are medical devices that use low-dose X-rays to examine the breast architecture and diagnose breast cancer. It's a minimally invasive screening technique that can detect breast cancer before symptoms appear. Mammography Devices uses various approaches such as computer-aided detection, digital mammography, and breast tomosynthesis. It is commonly used to screen patients showing signs of breast cancer like lumps or discomfort. During mammography, the patient's breast is placed on a support plate and compressed with a paddle while a burst of X-rays passes through to a detector. The resulting mammograms capture images of the breast tissue, with low-density tissues appearing translucent and dense tissues or tumors appearing white.

Key Market Drivers

Growing Burden of Breast Cancer

The growing burden of breast cancer is increasing the demand for mammography devices, as early detection and accurate diagnosis are paramount in the battle against this pervasive disease. Breast cancer remains the leading cancer diagnosis among women worldwide, with approximately 2.3 million newly reported cases in 2022. That same year, the disease accounted for an estimated 670,000 female deaths globally, underscoring its substantial impact on healthcare systems and reinforcing the urgent need for scalable early detection and diagnostic solutions. Breast cancer is one of the most common forms of cancer among women worldwide, and its incidence continues to rise. In response to this alarming trend, mammography has emerged as an essential tool for screening and diagnosing breast cancer at its earliest and most treatable stages.

The demand for mammography devices has also been fueled by the increasing awareness of the benefits of early detection and the continuous advancements in imaging technology. Innovations like 3D mammography provide clearer and more detailed images, reducing the likelihood of false positives and false negatives. Additionally, the development of more comfortable and patient-friendly Mammography Devices has encouraged more women to undergo regular screenings, further contributing to the demand for these devices.

The growing burden of breast cancer has placed a heightened emphasis on the need for effective and accessible screening methods. Mammography devices have emerged as vital tools in the fight against breast cancer, and their demand is expected to continue rising as healthcare systems globally strive to improve early detection rates, reduce mortality, and enhance the overall quality of care for breast cancer patients.

Technological Advancements in the Field of Breast Imaging

Technological advancements in the field of breast imaging are driving an increased demand for mammography devices, revolutionizing the way breast cancer is detected and diagnosed. These innovations are essential in improving the accuracy, efficiency, and patient experience associated with breast screenings. Digital mammography represents a significant leap forward from traditional film-based systems. It provides clearer and more easily manipulated images, reducing the need for retakes and enabling radiologists to detect abnormalities with greater precision. Moreover, the integration of computer-aided detection (CAD) software with digital mammography has enhanced the diagnostic capabilities by helping identify subtle lesions that might be overlooked by human eyes.

The introduction of 3D mammography, or tomosynthesis, has been a game-changer in breast imaging. This technology creates three-dimensional images, allowing radiologists to examine breast tissue layer by layer. This significantly reduces the incidence of false positives and false negatives, leading to more accurate diagnoses and fewer unnecessary follow-up tests.

Technological advancements have also led to improvements in patient comfort during mammography procedures. Ergonomically designed mammography devices and softer compression techniques have made the experience less painful and intimidating for women, encouraging more frequent and timely screenings. Furthermore, the integration of artificial intelligence (AI) into mammography is poised to further transform breast imaging. AI algorithms can assist radiologists in detecting subtle abnormalities, streamline workflow, and reduce interpretation time, making the entire process more efficient.

Increasing Mature Markets

Most of the growth in the global mammography market can be attributed to the mature markets of Western Europe, North America, South Korea, and Japan. These markets have well-established breast cancer screening programs that are adequately funded and reimbursed. Additionally, they boast a relatively high level of awareness, participation, and coverage when it comes to breast cancer screening.

One key factor contributing to the growth of these mature markets is the presence of a large installed base of equipment. As a result, purchases in these markets are often cyclical, aimed at replacing outdated equipment. However, it is worth noting that the year 2018 witnessed a unique trend in these markets. The demand for replacement equipment reached its peak due to a combination of factors.

During this period, there was an increase in breast cancer incidence and mortality rates, which coincided with improved awareness, coverage, and participation in breast cancer screening programs. This led to a surge in demand for new Mammography Devices. Moreover, stronger economies in these regions resulted in increased funding for healthcare providers. As a result, they were able to replace outdated systems with more advanced Mammography Devices, thereby driving uncharacteristically high growth in the mature mammography markets.

Investment from Various Organizations in Breast Cancer Screening Campaigns

Government sponsorship of mammography, primarily through the implementation of breast cancer screening programs, plays a significant role in shaping a nation's mammography market in terms of size and development. However, it is important to note that not all screening programs have equal impact on the market. Generally, nations with well-established screening programs tend to have larger and more mature mammography markets, whereas the absence of such programs results in smaller emerging markets. The unique needs and demands of their respective breast cancer screening programs contribute to the growth of mature and emerging mammography markets, thus influencing global mammography revenue. The increasing investment from various organizations in breast cancer screening campaigns is playing a pivotal role in driving up the demand for mammography devices. Breast cancer remains a significant global health concern, and organizations, both public and private, recognize the importance of early detection as a cornerstone in the fight against this disease.

Investments in breast cancer screening campaigns are primarily aimed at raising awareness and encouraging women to undergo regular mammography screenings. These campaigns often include educational initiatives, outreach programs, and advocacy efforts to emphasize the importance of early detection and the benefits of mammography in improving survival rates. As a result, more women are becoming aware of the necessity of regular breast screenings, which directly contributes to the increased demand for mammography devices. Furthermore, research organizations and charities invest in cutting-edge technologies and research to enhance the sensitivity and accuracy of mammography devices. This encourages the development and adoption of advanced Mammography Devices, such as digital mammography and 3D tomosynthesis, which further stimulates demand as healthcare providers seek to offer the latest and most effective breast imaging solutions to their patients.

Investment from various organizations in breast cancer screening campaigns is instrumental in raising awareness, improving accessibility, and advancing technology in the field of breast imaging. This collective effort significantly increases the demand for mammography devices, as more healthcare facilities strive to provide state-of-the-art breast cancer screening services to their communities, ultimately leading to earlier detection and improved outcomes for breast cancer patients.

Download Free Sample Report

Key Market Challenges

Reduction in Reimbursement

The reduction in reimbursement rates for mammography services is having a negative impact on the demand for mammography devices. Mammography is a critical tool in the early detection of breast cancer, and its accessibility is crucial for ensuring that women receive timely and effective screening. When reimbursement rates decrease, it creates several challenges that can deter healthcare providers from investing in or maintaining mammography devices. Reduced reimbursement rates directly affect the financial viability of offering mammography services. Healthcare facilities often rely on reimbursements from government programs and private insurers to cover the costs associated with Mammography Devices, staffing, maintenance, and overhead. When reimbursement rates are lowered, it can lead to financial losses for providers, making it less economically feasible to maintain or invest in modern mammography technology.

Lower reimbursement rates may lead to a reduction in the number of facilities offering mammography services. Smaller healthcare providers and clinics, in particular, may find it increasingly difficult to sustain mammography programs under reduced reimbursements, potentially limiting access to screenings for women in underserved or rural areas. Moreover, decreased reimbursement rates may discourage healthcare providers from investing in advanced mammography technology, such as 3D tomosynthesis or digital mammography, which can improve the accuracy of breast cancer detection. Providers may opt for older, less costly equipment that may not offer the same level of diagnostic capability.

Risk of Adverse Effects from Radiation Exposure

The risk of adverse effects from radiation exposure is a significant factor contributing to concerns and, in some cases, a decrease in the demand for mammography devices. While mammography is an invaluable tool for breast cancer screening and early detection, the exposure to ionizing radiation during the procedure has raised apprehensions among patients and healthcare providers.

One primary concern is the cumulative radiation dose over a woman's lifetime, especially for those who undergo routine mammograms. Prolonged exposure to ionizing radiation carries a potential risk of causing DNA damage and an increased likelihood of cancer development, albeit at relatively low levels. This heightened awareness of radiation risks has prompted some individuals to question the frequency of mammography screenings, potentially reducing demand for the service.

Additionally, women who may be particularly sensitive to radiation or have a higher genetic predisposition to radiation-induced cancers may express reluctance to undergo mammography. This can deter healthcare providers from recommending mammograms and, subsequently, impact the demand for mammography devices. While the risk of adverse effects from radiation exposure is a valid concern associated with mammography, advances in technology have helped mitigate these worries to some extent. The adoption of lower-dose mammography options is crucial in maintaining confidence in the safety of breast cancer screenings, thereby ensuring that the demand for mammography devices remains steady and that women continue to receive the benefits of early breast cancer detection.

Key Market Trends

AI and Computer-Aided Detection (CAD)

Artificial intelligence and machine learning algorithms are being integrated into mammography devices to aid radiologists in identifying abnormalities and improving the accuracy of interpretations. AI-powered CAD systems will likely become more advanced, helping to streamline the reading process and reducing interpretation errors. AI algorithms are trained on large datasets of mammograms to learn patterns associated with normal and abnormal breast tissue. These algorithms can detect subtle changes, microcalcifications, masses, or architectural distortions that might be indicative of cancer. They analyze the mammography images pixel by pixel, identifying areas that warrant closer inspection.

AI-driven CAD systems can significantly reduce false positives and false negatives. False positives can cause unnecessary anxiety and follow-up procedures, while false negatives can lead to missed cancer diagnoses. AI can help radiologists pinpoint potential abnormalities more accurately, reducing these errors. AI-powered CAD systems can help radiologists streamline their workflow. They can highlight areas of concern on the mammogram, making it quicker for radiologists to review the images and focus their attention on regions that may require further evaluation. This efficiency can lead to faster interpretation of mammograms. AI and machine learning are transforming mammography by improving the accuracy of interpretation, reducing errors, and enhancing radiologists' workflow. As these technologies continue to advance, they are likely to become an integral part of breast cancer screening, ultimately leading to earlier detection and improved outcomes for patients.

Portable and Point-of-Care Mammography

Smaller, portable mammography devices and point-of-care systems will become more prevalent, enabling screenings in non-traditional settings like mobile clinics and remote healthcare facilities. These devices will be especially valuable in increasing access to mammography in resource-constrained areas. Portable mammography devices are designed to be compact and lightweight, making them easy to transport. This mobility allows healthcare providers to take mammography services to remote or underserved regions where access to traditional healthcare facilities may be limited.

These devices are ideal for use in mobile healthcare clinics or vans, which can travel to rural or remote communities. Mobile clinics equipped with portable mammography units can provide on-site breast cancer screenings, eliminating the need for patients to travel long distances for a mammogram. Portable mammography devices are well-suited for use in smaller, remote healthcare facilities that may lack the space or infrastructure for larger, fixed mammography machines. These devices can be set up in primary care clinics, community health centers, or even temporary medical camps.

Portable mammography systems typically require less infrastructure and shielding compared to their larger, fixed counterparts. This can significantly reduce the cost of setting up and maintaining a mammography facility, making it more feasible for resource-constrained areas to offer breast cancer screening services. The ability to conduct mammography screenings in non-traditional settings means that women in underserved areas are more likely to receive timely breast cancer screenings. Early detection is crucial for improving outcomes, and portable devices help bridge the gap in access to healthcare. Portable mammography devices can also be invaluable during disaster response efforts. In the aftermath of natural disasters or humanitarian crises, they can be quickly deployed to ensure that breast cancer screenings continue for affected populations.

Segmental Insights

Technology Insights

Based on technology, the digital mammography segment emerges as the fastest growing segment in the Global Mammography Devices Market. Digital mammography utilizes solid-state detectors to convert X-rays into electrical signals, offering superior image acquisition and storage compared to traditional screen-film mammography. The transition from analog to digital systems has been accelerated by innovations such as: Offers high-resolution images that allow for better visualization of breast tissues, especially in women with dense breasts. Enables enhanced interpretation of images, supporting radiologists in identifying potential abnormalities. Facilitates real-time sharing and remote consultations, which is particularly valuable in multi-site healthcare networks.

Digital mammography is associated with faster image acquisition, shorter exam times, and lower radiation doses, improving both patient experience and clinical throughput. Key benefits include: Enhanced image clarity and manipulation capabilities (e.g., zoom, contrast adjustment), leading to earlier and more accurate detection of breast cancer. Reduced recall rates and fewer false positives, resulting in better clinical outcomes and lower downstream healthcare costs. Better performance in dense breast tissues, a significant advantage over analog techniques.

End User Insights

Based on the end user segment, hospitals and clinics dominated the Global Mammography Devices market during the forecast period. Hospitals and clinics serve as the first point of contact for a significant proportion of the population seeking medical care, including routine cancer screenings. Key centers for early breast cancer detection and diagnosis. Providers of regular screening services for women above the age of 40, in alignment with global clinical guidelines. Preferred institutions for follow-up procedures, biopsies, and treatment planning, all of which are linked to mammography results. The volume of diagnostic procedures conducted in hospitals and clinics is substantially higher than in standalone imaging centers, supporting greater utilization of mammography devices.

Hospitals particularly tertiary care and multi-specialty centers possess the financial resources and technical capacity to invest in high-end mammography systems, such as: Digital Breast Tomosynthesis (DBT) systems, AI-assisted mammography solutions, Full-Field Digital Mammography (FFDM) platforms. These facilities often have dedicated radiology departments and integrated IT systems (e.g., PACS, RIS), making it easier to deploy, manage, and upgrade mammography technologies. Hospitals and clinics are typically equipped to offer end-to-end breast health services, including: Initial consultation and screening, Diagnostic imaging (e.g., mammograms, ultrasounds), Histopathological testing (e.g., biopsies), Treatment planning and surgical interventions. This continuum of care not only increases the reliance on mammography devices but also enhances patient trust, encouraging repeat visits and long-term monitoring.

Download Free Sample Report

Regional Insights

Based on region, The North America region, led by the United States and Canada, has firmly established itself as the largest market in the global mammography devices industry. This regional dominance is underpinned by a convergence of advanced healthcare infrastructure, strong regulatory support, early adoption of cutting-edge technologies, and a high level of awareness about breast cancer screening. Together, these factors create a conducive environment for widespread adoption, utilization, and continuous innovation in mammography solutions. In the United States, approximately 12% of women equivalent to one in eight are projected to develop invasive breast cancer over the course of their lifetime. Epidemiological data indicates a sharp rise in incidence beginning at age 40, with the majority of new diagnoses occurring in women within this age group and older.

North America possesses one of the most technologically advanced healthcare systems in the world, with well-equipped hospitals, diagnostic imaging centers, and outpatient clinics. High per capita healthcare expenditure, allowing for significant investments in modern diagnostic technologies. Widespread access to digital mammography and 3D breast tomosynthesis systems, especially in urban and suburban areas. Robust integration of IT systems like PACS, RIS, and AI-powered analytics, improving workflow efficiency and clinical decision-making. This advanced infrastructure supports large-scale deployment and utilization of mammography devices, boosting market size.

The U.S. Food and Drug Administration (FDA) plays a key role in ensuring the safety and efficacy of medical imaging technologies. The Mammography Quality Standards Act (MQSA) mandates strict quality standards for mammography services and equipment, thereby: Driving the adoption of high-performance and compliant mammography devices. Ensuring regular device upgrades to maintain certification and performance standards. Creating a favorable environment for early commercialization and clinical use of new technologies, such as AI-enabled mammography and contrast-enhanced mammography. This regulatory clarity and oversight instill confidence among healthcare providers and patients alike, encouraging consistent use.

Recent Developments

• In June 2025, Arvinas, Inc. in collaboration with Pfizer Inc., has formally submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vepdegestrant, a targeted therapy for patients with ER-positive/HER2-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer who have progressed following prior endocrine-based treatments. The submission marks a critical regulatory milestone for a first-in-class estrogen receptor degrader, aiming to address a clinically challenging patient population with limited treatment options.
• In May 2025, The American Society of Clinical Oncology (ASCO) has issued revised guidelines regarding the clinical use of sentinel lymph node biopsy (SLNB) in breast cancer management. These updated recommendations are expected to substantially impact current surgical and diagnostic protocols, potentially leading to more selective use of SLNB based on tumor characteristics and patient profiles. The shift reflects an evidence-based effort to optimize patient outcomes while minimizing procedural interventions.
• In April 2025, A novel immunotherapy strategy developed with funding from Breast Cancer Now has demonstrated encouraging preclinical results in targeting treatment-resistant breast cancer. Researchers have engineered a next-generation antibody designed to activate the immune system against cancer cells, effectively reducing tumor progression. This breakthrough offers a potential therapeutic pathway for patients whose tumors have proven unresponsive to conventional treatment modalities, signaling a significant advancement in precision oncology.
• In February 2025, Researchers have engineered a new class of light-activated compounds, known as cyanine-carborane salts, that demonstrate high therapeutic efficacy against aggressive cancers with minimal off-target effects. In preclinical mouse models, this photodynamic approach achieved complete eradication of metastatic breast cancer tumors. Detailed in Angewandte Chemie, the findings position these compounds as a promising platform for next-generation oncologic therapies, offering a targeted, low-toxicity alternative to conventional treatment regimens.
• In January 2025, AstraZeneca and Daiichi Sankyo have received U.S. FDA approval for Datroway (datopotamab deruxtecan, Dato-DXd) for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer specifically those classified as IHC 0, IHC 1+, or IHC 2+/ISH- who have previously undergone endocrine-based therapy and chemotherapy for advanced disease. This approval represents a key advancement in addressing treatment-resistant tumors within a well-defined patient subgroup with historically limited therapeutic options.
• In January 2025, The U.S. FDA has granted approval for trastuzumab deruxtecan (T-DXd; Enhertu) as the first HER2-targeted therapy available in the United States for adult patients with unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer, based on results from an FDA-approved diagnostic test. According to AstraZeneca, the manufacturer, eligibility is limited to patients whose disease has progressed following at least one line of endocrine therapy, marking a significant expansion in therapeutic options for a previously underserved molecular subgroup.
• In October 2024, The U.S. FDA has approved inavolisib (Itovebi) in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer, following disease recurrence during or after adjuvant endocrine therapy. Concurrently, the FDA also authorized the use of the FoundationOne Liquid CDx assay as a companion diagnostic to identify eligible patients, reinforcing a precision medicine approach for this genetically defined subset.

Key Market Players

• Hologic, Inc.
• Fujifilm Holdings Corporation
• Philips Healthcare
• Siemens Healthineers AG
• GE Healthcare
• Carestream Health, Inc.
• Konica Minolta Inc.
• Delphinus Medical Technologies, Inc.
• Analogic Corporation
• KUB Technologies, Inc.

Report Scope:

In this report, the Global Mammography Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Mammography Devices Market, By Product Type:

o   Full-field Digital Mammography

o   Film-screen Mammogram

o   Breast Tomosynthesis

• Mammography Devices Market, By Technology:

o   Digital

o   Analog

• Mammography Devices Market, By End User:

o   Hospitals & Clinics

o   Diagnostic Centres

o   Others

• Mammography Devices Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Mammography Devices Market.

Available Customizations:

Global Mammography Devices market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Mammography Devices Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]